An Epidemiological Prospective Cohort Study to Describe Treatment Patterns of Fulvestrant And ExemeSTane in Postmenopausal Patients With Advanced HR+ Breast Cancer Under Real-life Conditions in GERmany.
Phase of Trial: Phase IV
Latest Information Update: 13 Dec 2013
At a glance
- Drugs Exemestane (Primary) ; Fulvestrant (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms ACT-FASTER
- Sponsors AstraZeneca
- 01 Nov 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 07 Jan 2013 Planned end date changed from 1 Sep 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.